Merck & Co., Inc. (MRK) earnings on April 30, 2026
More Merck & Co., Inc. earnings
Prior outlook: No statistical edge
MRK's stock price declined after its earnings report, despite positive news leading up to it. The shares ended the day lower.
MRK price around the earnings
109.17
Change: -1.7%
2026-04-30, 19:59 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: No statistical edge
- Thesis published
Positive news and analyst support suggest potential upside.
Positive news regarding drug approvals is a key driver, with analysts maintaining strong buy ratings and expecting the stock price to rise. Despite some recent price weakness, the outlook is constructive.
Context analyzed before publication
- Summary
- Positive news and analyst support suggest an optimistic scenario.
- Reasoning
- Positive news regarding drug approvals is a key driver, with analysts maintaining strong buy ratings and citing an optimistic scenario. Despite some recent price weakness, the outlook is constructive.
- Playbook
- The recent drug approval is a significant positive development, and with analysts maintaining strong buy ratings, the scenario is optimistic.
- Trend
- Recent pullback stabilizes; positive news supports setup.
Analysts
Drivers
-
Analysts
Positive
Analysts generally hold a strong positive view, maintaining a buy rating with a target price citing an optimistic scenario. Major financial institutions are confident in the company.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.83
- Analysts covering the stock
- 27
- Average price target
- 129.81
- Lowest price target
- 100
- Highest price target
- 150
- Upside to price target
- 15.3%
- Quarterly earnings growth
- -20.8%
- Revenue growth
- 5%
- Forward EPS
- 9.72
- Trailing EPS
- 7.28
- Analyst moves in the last 60 days
- 6
- Strong buy: 4
- Buy: 15
- Hold: 10
- Sell: 0
- Strong sell: 0
- Strong buy
- 4
- Buy
- 15
- Hold
- 10
- Sell
- 0
- Strong sell
- 0
- April 13, 2026 · UBS: Maintains rating (Buy → Buy)
- April 6, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)
- March 30, 2026 · RBC Capital: Reiterates rating (Outperform → Outperform)
- March 20, 2026 · Citigroup: Maintains rating (Neutral → Neutral)
- March 12, 2026 · Wells Fargo: Maintains rating (Overweight → Overweight)
- February 25, 2026 · RBC Capital: Initiates coverage (Outperform)
News and sentiment
Drivers
-
News & sentiment
Positive
The company received important approval from health authorities for a new treatment. This positive regulatory news is a significant factor, outweighing any recent dips in the stock's price.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (6)
- Why Is Merck Stock Falling Tuesday? — Benzinga
- FDA Approves Merck's IDVYNSO For HIV-1 Infection Treatment In Adult Patients — Benzinga
- Merck Announces Results From Phase 3 LITESPARK-012 Trial Evaluating Combination Regimens For First-Line Treatment Of Patients With Advanced Clear Cell Renal Cell Carcinoma — Benzinga
- Merck Announces FDA Priority Review for KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Padcev, For The Treatment Of Patients With Muscle-Invasive Bladder Cancer, With PDUFA Date Set For August 17 — Benzinga
- Merck Says EC Approves ENFLONSIA For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Newborns And Infants — Benzinga
- UBS Maintains Buy on Merck & Co, Raises Price Target to $145 — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's recent performance has lagged the broader market, showing weakness. However, its price is near a support level, suggesting it might be oversold and could potentially see a shift to a more optimistic reading.
Evidence
- Average true range (ATR)
- 2.8%
- Distance to 52-week high
- -10.1%
- 14-day change (14d)
- -6.9%
- 30-day change
- -3.9%
- 30-day relative strength
- -7.7%
- Benchmark change
- +3.8%
- Nearest support
- 111.95
- Nearest resistance
- 123.97
- Volume accumulation ratio
- 0.87
Trends
Evidence
- Average earnings surprise
- -2.6%
- February 3, 2026: actual EPS 1.19 vs estimate 1.68 (surprise -29.2%)
- October 30, 2025: actual EPS 2.58 vs estimate 2.35 (surprise +9.8%)
- July 29, 2025: actual EPS 2.13 vs estimate 2.03 (surprise +5.0%)
- April 24, 2025: actual EPS 2.22 vs estimate 2.14 (surprise +4.0%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 2.2%
- 75th percentile move
- 4.2%
- 90th percentile move
- 6.8%
- Up / down moves
- 9 / 10
- Average up move
- +3.0%
- Average down move
- -3.5%
Monitoring and close
What Merck & Co., Inc. reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Consolidated
- -1.7%
- Max move
- -2.1%
No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.